Acknowledgment
David A.
RECRUITMENT, MITOCHONDRIAL DISEASE, BROWN
The authors thank the investigators, healthcare providers, research staff, participants, and caregivers who participated in the MMPOWER-3 study. The authors thank the following staff who have significantly contributed to the study: Erica Lynn Kelly and Michele Guyette, Massachusetts General Hospital, Boston, MA, United States. Statistical analyses were performed by the biostats team at Everest Clinical Research, Everest Clinical Research Corp, Markham, ON. Post hoc analyses were performed by Jeffrey S. Finman, PhD. Jupiter Point Pharma Consulting, LLC. Writing and editing assistance, including preparation of a draft manuscript under the direction and guidance of the authors, incorporating author feedback, was provided by James A. Shiffer, RPh (Write On Time Medical Communications, LLC), David A. Brown, PhD. (Stealth BioTherapeutics), and Gene Kelly, RPh (Stealth BioTherapeutics). The authors thank Jim Carr, PharmD, and Anthony Aiudi, PharmD (Stealth BioTherapeutics) for their support of the clinical study endpoints, statistical analysis, and interpretation of the study results. The authors also thank the Mito Action and United Mitochondrial Disease Foundation for helping with recruitment. They also acknowledge TCRC/Harvard Catalyst (Class of Evidence: Null Hypothesis: 